Policy / Pricing FDA Policy Tracker 2026: Psychedelics get a boost BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Policy / PricingNeuroscienceRead full story Post navigation Previous: UK Knowledge Quarter welcomes Boehringer Ingelheim AI acceleratorNext: Beyond GLP-1Rs: emerging targets poised to gain share of obesity market Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
